Abstract

Objectives: Cancer related anemia is common comorbid treatable condition with potential impact on treatment response and quality of life. Data on treatment with ferric carboxymaltose (FCM) an i.v. iron preparation in cancer related anemia due to iron deficiency in Indian patients is sparse.

Materials and Methods: In this retrospective medical record based study, data of 147 patients with solid organ malignancies and iron deficiency anemia (IDA) who received FCM were retrieved. Hematological parameters i.e. hemoglobin (Hb), serum ferritin and transferrin saturation (TSAT) were analyzed at baseline (i.e. before FCM administration) and at 4 weeks. Serious adverse events which were recorded in source documents on day of FCM infusion were collected.

Results: At the baseline, mean Hb was 8.7±1.2 gm/dl. At end of 4 weeks there was a statistically significant improvement in the mean Hb level of 9.79±0.87 (p value <0.001). The mean serum ferritin and serum TSAT level also showed a significant improvement (p value for both < 0.001). No SAE were recorded on day of FCM administration

• 1.   Anand S, Burkenroad A, Glaspy J. Workup of anemia in cancer. Clin Adv Hematol Oncol. 2020;18(10):640–646.
• 2.   Kanuri G, Sawhney R, Varghese J, Britto M, Shet A. Iron deficiency anemia coexists with cancer related anemia and adversely impacts quality of life. PLoS One. 2016;11(9):e0163817.
• 3.   Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv96–iv110.
• 4.   Griffiths EA, Alwan LM, Barta SK, et al. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw. 2022;20(5):436–442.
• 5.   Bahl A, Sharma DN, Basu J, Rath GK, Julka PK. Pre-treatment anemia evaluation in cancer patients attending radiotherapy clinic: results from a single Indian center. Indian J Med Sci. 2008;62(10):417–420.
• 6.   National Comprehensive Cancer Network. NCCN Guidelines for Patients: Anemia and Neutropenia [Internet]. Plymouth Meeting (PA): NCCN; 2021 [cited 2026 Jan 20]. Available from: https://www.nccn.org/patients/guidelines/content/PDF/anemia-neutropenia-patient.pdf
• 7.   Wu T, Tong Z, Ren T, Xie D, Sun X. Effect of erythropoiesis-stimulating agents on breast cancer patients: a meta-analysis. Clin Exp Med. 2022;23(5):1489-1499.
• 8.   Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29(11):2075–2084.
• 9.   Trivedi P, Dave N, Sanghvi J, et al. Ferric carboxymaltose in the management of iron deficiency anemia in pregnancy: a subgroup analysis of a multicenter real-world study involving 1191 pregnant women. Obstet Gynecol Int. 2022;2022:5759740.
• 10.   Abdel-Razeq H, Hashem H, Mansour A, et al. Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents. Ther Adv Med Oncol. 2020;12:1758835920953292.
• 11.   Pandey A, Singh S, Aryan R, Murari K. Prevalence of iron, Vitamin B12 deficiency and inflammatory anaemia in treatment naive individual consecutive cancer patients: a cross sectional study [Preprint]. medRxiv. 2020 Jul 31. Available from: https://doi.org/10.1101/2020.07.29.20164426
• 12.   John GK, Sanamandra S, Shet AS. Cancer related anemia in the developing world: risk factors and treatment patterns. Blood. 2011;118(21):4747.
• 13.   Sharma P, Gupta A, Sharma R, et al. Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: prevalence, risk factors, cost and effect on disease outcome. Support Care Cancer. 2022;30(6):5519–5526.
• 14.   Sundriyal D, Nayak PP, Arya L, Walia M, Saha R. Evaluation of iron status in patients of solid organ malignancies: study from a cancer research centre. Indian J Surg Oncol. 2020;11(1):56–59.
• 15.   Grotto HZW. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol. 2008;25(1):12–21.
• 16.   Abiri B, Vafa M. Iron deficiency and anemia in cancer patients: the role of iron treatment in anemic cancer patients. Nutr Cancer. 2020;72(5):864–872.
• 17.   Buchrits S, Itzhaki O, Avni T, Raanani P, Gafter-Gvili A. Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2022;11(14):4156.
• 18.   Calleja JL, Delgado S, del Val A, et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Colorectal Dis. 2016;31(3):543–551.
• 19.   Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475–482.
• 20.   Nath UK, Chetia R. PB2045 Efficacy & safety of intravenous ferric carboxymaltose in iron deficiency anemia: a prospective study. HemaSphere. 2019;3(S1):922.
• 21.   Gupte SA, Venkataraman G, Shah AS, Mudholkar AS, Jangam SM. Clinical effects and safety of ferric carboxymaltose in pregnancy: an Indian real-life experience. J Obstet Gynaecol Res. 2021;47(10):3464–3470.

Data Sharing Statement

Funding